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Over 150 years ago, Virchow (1) first postulated that a triad
of conditions predispose to thrombus formation, these three
factors being abnormalities in blood flow, blood constitu-
ents and the vessel wall. While Virchow was referring to
venous thrombosis, the same processes have been applied to
arterial thrombosis. A contemporary viewpoint of Virchow’s
triad considers abnormalities of hemorheology and turbu-
lence at bifurcations and stenotic regions (i.e., abnormal
blood flow), abnormalities in platelet function and the
coagulation and fibrinolytic pathways (abnormal blood con-
stituents) and finally, abnormalities in the endothelium
(abnormal vessel wall). As the processes of thrombogenesis
and atherogenesis are intimately related, there is perhaps
little surprise that thrombogenesis has been studied exten-
sively in cardiovascular disease.
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Improvements in laboratory techniques have allowed us
to quantify various components of Virchow’s triad, which, if
abnormally elevated, confer the presence of a so-called
“prothrombotic” or “hypercoagulable” state. Such abnormal-
ities in certain indexes of hypercoagulability (such as fibrin-
ogen) have been found in cardiovascular diseases as diverse
as coronary artery disease (CAD), atrial fibrillation and
heart failure (2–5). This prothrombotic state has been
related to target organ damage and cardiovascular risk as
well as prognosis, and it can be modified by interventions
such as antithrombotic and antiplatelet therapy (6–10).
More recently, the importance of the fibrinolytic pathway is
becoming apparent as high levels of the principal inhibitor
of this process (plasminogen activator inhibitor-1, PAI-1)
also predict the development of ischemic events (11–13). It
follows that one may postulate that the high-risk patients
with evidence of ongoing thrombogenesis and abnormal
fibrinolysis, which are important facets of the prothrom-
botic state, are more likely to exhibit greater hypercoagula-
bility.
From the cardiologist’s perspective, one particularly high-
risk population of patients is represented by the acute
coronary syndromes. It is therefore of little surprise that the
abnormalities in the prothrombotic or the hypercoagulable
state in CAD have been related to the acute coronary
syndromes or myocardial infarction (MI), and so rightly
continue to provide fertile research opportunities. For ex-
ample, in this issue of the Journal, Figueras et al. (14) extend
this relationship further by reporting abnormalities in
thrombin-antithrombin complex, D-dimer, fibrinogen and
PAI-1 antigen in 40 patients with acute MI and 23 patients
with unstable angina. The markers were measured upon
hospital admission, at 10 days, and importantly, at three
months’ follow-up. They find that patients who developed
recurrent angina while in the hospital had higher PAI levels
than those who were free of angina, indicating higher
inhibition of fibrinolysis and greater thrombin generation.
This therefore supports the developing concept that ade-
quate fibrinolysis is a valuable component in the rapid return
to health (11–13).
However, further interesting questions arise from this
article. The time of pain onset to first blood sampling
ranged between 1 h 15 min and 18 h 10 min in patients with
unstable angina, and 1 h 22 min to 17 h 30 min in those
with acute MI. If we postulate that thrombogenesis is an
active ongoing dynamic process, patients sampled 1 to 2 h
after pain onset are likely to have a different coagulation
and/or fibrinolytic activation profile when compared with
those sampled at 17 to 18 h after pain onset, given the short
half-lives of many of these molecules. Furthermore, patients
who may be symptomatically stabilized may yet continue to
have underlying “silent” angina. If thrombogenesis is related
to underlying acute ischaemia, then such patients would
certainly manifest an abnormal prothrombotic state that
would need to be studied further.
Myocardial infarction is often associated with mural
thrombus and/or associated heart failure or atrial fibrillation
(4,5), which can all alter markers of thrombogenesis and can
perhaps be further confounding factors. Indeed, the greater
myocardial damage in MI compared with unstable angina
may release several cytokine mediators, such as
interleukin-6, resulting in a more marked acute phase
response with different effects on thrombogenesis and fibri-
nolysis—perhaps explaining some of the observations in this
article (14). Many drugs, such as the angiotensin-converting
enzyme inhibitors and heparin, as well as contrast media
from the subset undergoing cardiac catherization or angio-
plasty, can also influence the measured parameters.
As apparent in the article by Figueras et al. (14), the use
of thrombolytic therapy during the treatment of acute MI
results in further generation of fibrin degradation products,
including fibrin D-dimer (which they measure). Previous
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reports have suggested that the maximum rise in fibrin
D-dimer is seen between 1 and 4 h, but importantly,
elevations in fibrin D-dimer levels do not appear to be
predictive of coronary patency (15,16). However, it is
important to note that only a fraction of the elevation in
fibrin D-dimer is actually due to lysis of coronary thrombi,
and most derive from other types of intravascular fibrin (17)
for example, the lysis of cross-linked circulating fibrin
polymers. Measurement of peripheral fibrin D-dimer levels
after thrombolytic therapy for acute MI therefore does not
distinguish between these two potential sources of D-dimer,
and as the article from Figueras et al. (14) suggests, there is
little role for the routine measurement of fibrin D-dimer
after thrombolytic therapy for acute MI. The increase in
fibrin D-dimer levels also appears to be independent of the
type of thrombolytic agent used and of the clinical course
following the infarct (18).
The observations linking the prothrombotic state and
cardiovascular disease are nevertheless important in view of
the relationship between these markers and both short- and
long-term cardiovascular outcomes. For example, hyperten-
sive subjects with plasma fibrinogen levels .3.5 g/liter had
a 12-fold higher cardiovascular risk than those with plasma
fibrinogen levels ,2.9 g/liter in the Leigh general practice
study (19). In a study of 617 patients with claudication, the
Edinburgh Artery Study reported that baseline fibrin
D-dimer levels were closely related to future coronary events
(both fatal and nonfatal, with a relative risk of 4.4 between
upper and lower quintiles) and also with hemodynamic
progression of peripheral arterial disease (6). Indeed, higher
plasma levels of fibrin degradation products have been found
in patients suffering thrombotic reocclusion following fem-
oropopliteal artery angioplasty, when compared with pa-
tients with maintained patency of the dilated arterial seg-
ment (20). Indeed, indexes of a prothrombotic or
hypercoagulable state, even within the “normal” laboratory
range, can predict both arterial thrombotic events and
postoperative thrombosis (6,10,21), suggesting that there
may be a continuum between health, a “statistical” increase
in (say) fibrin turnover as a prethrombotic state, and
“overtly” increased fibrin turnover in acute thrombosis (or
sometimes in acute extravascular fibrin formation, as follows
injury or surgery) (10). Importantly, increased thrombogen-
esis appears to contribute to the progression of both
coronary and peripheral atherosclerosis, which is consistent
with the hypothesis that markers such as fibrin D-dimer
may be a useful index of intravascular fibrin turnover and the
contribution of thrombosis to arterial disease (6,10–13).
Figueras et al. (14) also report that levels of the various
indexes measured were “significantly higher” than “con-
trols,” which comprised 25 healthy individuals with a mean
age of 47 years, compared with a mean age of 57.8 years in
the patient group. As the authors rightly point out, some
caution is needed in interpreting this statement in view of
the association between some of the measured indexes and
age. Furthermore, their use of symptomatic assessments
(i.e., angina vs. no angina) have some limitations, and
evaluations using measures of high risk such as troponins
would perhaps have been more valuable (22), especially if
they could be correlated with the indexes of thrombogen-
esis. Another question that may be raised is whether
subgroup analyses (e.g., 12 patients with unstable angina
who are compared with the 11 who did not develop angina
[14]) are adequately powered. Some parameters such as
D-dimer and thrombin-antithrombin are highly skewed so
that median (rather than mean) values would be more
representative of what is actually going on.
Would thrombogenesis or fibrinolysis represent a cause,
or an effect, in acute coronary syndromes or MI? Since the
processes of thrombogenesis and atherogenesis have many
similarities to inflammatory disease, the elevations in various
indexes may simply reflect the severity of the underlying
vascular disorders as a secondary phenomenon rather than
act as a true prognostic factor. Indeed, it has been suggested
that the associations between cardiovascular disease and the
prothrombotic state may be explained by a reactive or
secondary rise in plasma hemostatic factors, either as an
acute phase response or as a vascular disease-related “hema-
tological stress syndrome” (23). There is increasing recog-
nition of the parallel changes in the inflammatory response
in the pathogenesis of CAD, including the prediction of
subsequent cardiac events in patients with both unstable and
chronic coronary disease (24,25). Furthermore, in view of
possible relationships between Chlamydia pneumoniae and
Helicobacter pylori (26) with CAD, including acute coronary
syndromes, the role of potential pathogenic infections needs
to be defined. For example, some studies have suggested
that interventions with antibiotics to eradicate C pneumoniae
in patients with acute coronary syndromes may be benefi-
cial, although some of the antibiotics used have anti-
inflammatory effects (27,28). There is also the possibility
that thrombolytic therapy for acute MI may be related to an
increase in oxidative stress, platelet activation and endothe-
lial cell damage (29). Despite the diverse nature of (possible)
stimuli, the final common pathway linking abnormal
thrombogenesis and cardiovascular disease may well be
cytokine mediated (30), which opens the possibility of a
target for intervention.
The identification of ongoing thrombogenesis and fibri-
nolysis in patients with MI or acute coronary syndromes
represents facets of a prothrombotic or hypercoagulable
state and may possibly identify a high-risk subset of patients
who may develop complications. Large prospective studies
are required to carefully document the precise interactions
between the many components of Virchow’s triad and
clinical outcomes in cardiovascular disease.
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